Please login to the form below

Not currently logged in
Email:
Password:

Solymbic

This page shows the latest Solymbic news and features for those working in and with pharma, biotech and healthcare.

Amgen wins European approval for Humira biosimilar Amgevita

Amgen wins European approval for Humira biosimilar Amgevita

Meanwhile, in Europe Amgen’s new product has a duplicate marketing authorisation under the brand name Solymbic.

Latest news

  • Merck confirms sale of biosimilar division Merck confirms sale of biosimilar division

    In January, the EMA's Committee for Medicinal Products for Human Use (CHMP) backed approval of the Humira biosimilar under two brand names - Amgevita and Solymbic – with approval expected in the

  • Amgen's Humira biosimilars backed for EU approval Amgen's Humira biosimilars backed for EU approval

    Amgevita and Solymbic prepare to challenge AbbVie’s blockbuster. AbbVie's Humira (adalimumab) looks set to be on the defensive in Europe as well as the US this year, after the ... Amgen's biosimilars - Amgevita (ABP 501) and Solymbic - were recommended

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Evoke Kyne

Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...

Latest intelligence

Sustainability
Environment: where does the pharmaceutical industry stand?
...
The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...